drugset
drugset / Trial / NCT07801352

CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer

NCT07801352 ↗

Phase 2 Active not recruiting 15 enrolled Shanghai Changzheng Hospital
NaSingle-groupOpen-labelTreatment

Summary

This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with anti-PD1 antibody plus dihydroartemisinin as neoadjuvant or conversion therapy for pMMR/MSS locally advanced and metastatic colorectal cancer

Timeline

Start
2024-07-01
Primary completion
2025-07-28
Completion
2028-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule 20 mg Oral
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

colorectal cancer